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Abstract 
Background 
Endovenous thermal ablation has revolutionised varicose vein treatment.  New non-thermal 
techniques such as mechanical occlusion chemically assisted endovenous ablation (MOCA) 
allow treatment of entire trunks with single anaesthetic injections.  Previous non-randomised 
work has shown reduced pain post-operatively with MOCA.  This study presents a multi-
centre randomised controlled trial assessing the difference in pain during truncal ablation 
using MOCA and radiofrequency endovenous ablation (RFA) with 6-months follow-up. 
Methods 
Patients undergoing local anaesthetic endovenous ablation for primary varicose veins were 
randomised to either MOCA or RFA.  Pain scores using Visual Analogue Scale (VAS) and 
number scale (0-10) during truncal ablation were recorded.  Adjunctive procedures were 
completed subsequently.  Pain after phlebectomy was not assessed.  Patients were reviewed 
at 1 and 6 months with clinical scores, quality of life scores and duplex ultrasound 
assessment of the treated leg. 
Results 
170 patients were recruited over a 21-month period from 240 screened.  Patients in the 
MOCA group experienced significantly less maximum pain during the procedure by VAS 
(MOCA median 15mm (IQR 7-36mm) versus RFA 34mm (IQR 16-53mm), p=0.003) and 
number scale (MOCA median 3 (IQR 1-5) versus RFA 4 (IQR 3-6.5), p=0.002).  “Average” 
pain scores were also significantly less in the MOCA group.  74% underwent simultaneous 
phlebectomy.  Occlusion rates, clinical severity scores, disease specific and generic quality of 
life scores were similar between groups at 1 and 6 months.  There were two deep vein 
thromboses, one in each group. 
Conclusion 
Pain secondary to truncal ablation is less painful with MOCA than RFA with similar short 
term technical, quality of life and safety outcomes. 
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Introduction 
Varicose veins are a common condition worldwide and cause significant quality of life 
impairments with consequent healthcare costs 
1
.  Symptomatology is varied, as is progression 
to ulceration 
2,3
.  Endovenous ablation with catheter based technology, using radiofrequency 
energy or laser energy to cause thermal damage to the vein leading to fibrosis and occlusion, 
has revolutionised modern varicose vein treatment.  Now any superficial vein navigable by a 
soft hydrophilic guidewire can be treated in this manner.  These developments have led to 
endovenous thermal ablation being recommended as first line treatment by the National 
Institute for Health and Care Excellence (NICE) 
4,5
.  The aforementioned techniques however 
require the use of tumescent anaesthesia which involves multiple needle injections 
6
.  In the 
past few years new techniques have been developed and older techniques extended to 
alleviate the need for tumescent anaesthesia, and improve the patient experience. One of the 
new techniques is mechanical occlusion chemically assisted endovenous ablation  (MOCA), 
which uses a hybrid system of physical damage to the vein wall and liquid sclerotherapy to 
lead to scarring and fibrosis without the need for tumescent anaesthesia 
7,8
.  The lack of 
requirement for multiple needle injections should in theory lead to reduced intra-operative 
and peri-operative pain.  Recent work in a non-randomised study comparing RFA and 
MOCA has shown a reduced pain experience post-operatively for those patients undergoing 
MOCA 
9
.  This study was designed to compare the pain levels encountered during the 
procedure between RFA (using the Medtronic Venefit RFA segmental catheter; Medtronic, 
Santa Rosa, California, USA) and MOCA (using the Vascular Insights Clarivein catheter; 
Vascular Insights, Quincy, Massachusetts, USA), with MOCA hypothesised to be less 
painful.  Initial results of this study have previously been published 
10
. 
 
Methods 
The trial protocol and methodology have previously been reported 
10
, and is described in full 
below.  The trial was registered with Current Controlled Trials and the ISRCTN registry 
(http://www.isrctn.com) (ISRCTN06552809).  The trial protocol, inclusion and exclusion 
criteria are freely available at http://www.isrctn.com/ISRCTN06552809.  Ethical approval 
was obtained from the United Kingdom National Research Ethics Service, London – Chelsea 
Committee (NRES) (Research Ethics Committee Reference: 12/LO/0570).  Imperial College 
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London were the trial sponsors (reference number JRCOHH0431). 
Patients 
Patients with symptomatic primary varicose veins with either GSV or SSV incompetence 
(>0.5s reflux on colour duplex ultrasound) presenting to Charing Cross Hospital (Imperial 
College Healthcare NHS Trust) or Northwick Park Hospital (London North West Healthcare 
NHS Trust) in London, UK were assessed clinically by independent clinicians and listed for 
treatment.  Clinical stage and symptom scores were recorded.  Once listed for treatment they 
were screened trial inclusion and invited to participate in the Venefit Versus Clarivein for 
Varicose Veins (VVCVV) trial.  Patients with recurrent varicose veins, current deep vein 
thrombosis, arterial disease (ankle brachial pressure index <0.8), veins <3mm in diameter or 
hypercoagulability were excluded from participation.  Additionally, patients unable or 
unwilling to complete questionnaires or to participate were also excluded.  Consenting 
participants were then randomised on the day of treatment to either MOCA (group one) or 
RFA (group two), using an online computerised randomisation software (SealedEnvelope, 
London, UK).  In patients with bilateral disease the most symptomatic side was entered into 
the study.  Patients completed generic and disease specific questionnaires prior to 
intervention. 
Interventions 
All procedures were carried out by trained vascular surgeons who were experienced in both 
techniques of endovenous ablation.  No peri-operative analgesia or sedation was used.  
Standard distraction techniques were utilised with music and verbal distraction.  Ultrasound 
guidance and local anaesthetic (and tumescent anaesthesia in the RFA group) were used in all 
procedures.  Initial vein access (GSV or SSV) was performed under ultrasound guidance after 
injection of local anaesthetic (1% Lidocaine using a standard 3cm length 23 Gauge needle), 
targeting the most distal point of venous reflux where cannulation was possible. A standard 
7Fr vascular sheath was placed (Medtronic, USA).  The treatment catheter tip was positioned 
2 cm distal to the sapheno-femoral junction or sapheno-popliteal junction, assessed in both 
longitudinal and transverse views on ultrasound. 
The standard method was used for RFA (Venefit, Medtronic, USA), as described before 
11
.  
Concisely, cooled tumescent anaesthesia (either 360 ml Normal Saline with 40 ml 1% 
lignocaine with 1:200000 adrenaline; or 500ml normal saline with 20ml 1% lignocaine and 
5ml 8.4% sodium bicarbonate, dependent on local protocol) was injected using a standard 
4cm length 21 Gauge needle into the saphenous sheath using a Klein pump at 400mls per 
minute to create a “1cm halo” of tumescent along the vein to be treated (approximately 10mls 
per cm).  Then RF segmental ablation was completed, with 20 seconds per treatment zone 
(7cm or 3cm dependent on catheter tip), and double treatment for the first segment. 
MOCA (Clarivein, Vascular Insights, USA) was performed as previously described 
9,10
 using 
2% sodium tetradecyl sulphate (STS) (Fibrovein
TM
, STD Pharmaceutical Products Ltd., 
Hereford, UK) (made by mixing equal volumes of 1% STS and 3% STS). Concisely, 
following cannulation and tip positioning under ultrasound guidance, the treatment tip was 
unsheathed and positioning rechecked.  The sclerosant syringe was then attached.  The device 
motor was engaged for 1-2 seconds to induce proximal vein spasm.  Then, the activated 
catheter with rotating tip was steadily withdrawn by 1 cm every 7 seconds, whilst injecting 
sclerosant at a constant rate dependent on length of vein to be treated and volume of 
sclerosant.  This sclerosant injection rates was calculated as per the manufacturer’s guidance. 
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Immediately after completion of the endovenous ablation, patients were asked to report their 
pain experience on a 0-100 mm Visual Analogue Scale and a 0-10 number scale. 
If required (if symptomatic visible varicosities) and with patient consent, concomitant 
phlebectomies were then performed using standard Oesch hook technique with local 
tumescent anaesthesia 
12,13
. 
All patients received a single prophylactic dose of low molecular weight heparin at the 
completion of the procedure.  Use of prophylactic antibiotics was left to the discretion of the 
treating surgeon. 
Stockings were worn for two weeks post-procedure, and patients were advised to return to 
their work and normal activities as soon as they felt able to. 
Patients were reviewed at 1 month and 6 months post procedure with clinical assessment, 
duplex ultrasound and asked to complete a questionnaire. 
Outcome Measures 
The primary outcome of the study was the degree of pain experience during endovenous 
ablation using a validated patient reported Visual Analogue Scale (VAS) and 0-10 number 
scale, prior to completion of any phlebectomies.  Patients were also asked to describe the 
duration of the pain as lasting seconds, minutes or several minutes.  The secondary outcomes 
were improvement in patient reported quality of life, both  disease specific (Aberdeen 
Varicose Vein Questionnaire - AVVQ) 
14
 and generic (Euroqol 5 Domain 3 Level - EQ-5D-
3L and EuroQol VAS) 
15
; clinical scores (Venous Clinical Severity Score -  VCSS, Venous 
Disability Score - VDS and Clinical Etiology Anatomy Pathology score - CEAP) 
16,17
 and 
time taken to return to normal activities and work.  The primary outcome measure was 
assessed at the time of intervention.  The secondary outcomes were assessed at 1 month and 6 
months post operative follow-up.  Technical success was also assessed at 1 month and 6 
months with validated, blinded venous duplex ultrasound scanning.  There were four possible 
scan classifications: complete occlusion of the saphenous vein, proximal occlusion (>5cm 
proximally occluded, with >5cm open distally), distal occlusion (>5cm distally occluded, 
with >5cm open proximally) and open.  Patency in the first 3cm of the GSV was considered 
normal 
18
. 
Power Calculations 
Power calculations were based on the primary outcome of pain during the truncal ablation 
procedure as assessed by VAS. Detection of a 20-mm difference in maximum pain score with 
a standard deviation (SD) of pain score of 20 mm was considered a significant difference. 
The minimum target size was calculated to be 94 patients (47 per group) at 90% power and 
5% significance. Allowing for loss to follow-up or protocol violations, an overall target 
recruitment of 170 legs (85 per group) was estimated. 
Statistical Analysis 
Data was recorded prospectively on a bespoke database and analysed using SPSS version 23 
(IBM, Armonk, USA), STATA version 14 SE (Statscorp, College Station, Texas, USA), 
Wizard Pro version 1.7.14 (Evan Miller, Chicago, Illinois, USA) and Prism version 6 
(GraphPad, La Jolla, California, USA).  Data was analysed using parametric and non-
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parametric statistical tests as dictated by distribution of data.  Normally distributed data is 
reported as mean and standard deviation (SD), non-normal distributions are reported as 
median and interquartile range (IQR). 
Results 
170 patients were recruited between January 2013 and September 2014 from a potential 240 
screened patients.  41% were male.  86% were GSV and 14% SSV.  Baseline data is 
presented in Table 1, there were no significant differences between groups.  87 were 
randomised to receive MOCA and 83 to RFA.  83 of the 87 MOCA cases underwent MOCA 
and 82 of the 83 RFA cases underwent RFA.  There was one crossover in each group.  
Analysis was performed on an intention to treat basis.  Treatment data is presented in Table 
2, there were no significant differences between procedural details, including number of 
patients having concomitant phlebectomies and number of phlebectomies performed.  See 
Figure 1 for the Trial Consort Diagram.  Proportion of patients completing follow-up at 1 
month was 76% (n=129) and at 6 months 71% (n=121). 
Primary Outcome 
Maximum Pain experienced during truncal ablation (Figure 2) 
Overall median maximum pain via VAS was 24mm (IQR 10-45) and 4 (2-5) by 0-10 number 
scale.  Maximum pain experienced during endovenous ablation as measured on VAS was 
significantly less in the MOCA group with a median of 15mm (IQR 7-36mm) versus 34mm 
(16-53mm), p=0.003 (Mann-Whitney).  As measured on a number scale of 0-10, median 
maximum pain experienced was also significantly less in the MOCA group - 3 (1-5) vs 4 (3-
6.5), p=0.002 (Mann-Whitney).  Post hoc power analysis demonstrated 91% power at 0.05% 
significance for the VAS and 94% power at 0.05% significance for the number scale.  VAS 
and number scale showed a very strong correlation (Pearson’s r = 0.96, p<0.001). 
86% of patients described the maximum pain as lasting seconds, and there was no difference 
in estimated duration of maximal pain duration between groups (90% seconds in MOCA 
group versus 82% seconds in RFA group, p=0.169). 
“Average” Pain experienced during truncal ablation (Figure 3) 
Overall median “average” pain experienced was 15mm (6-32) and 2.5 (1-4) by 0-10 number 
scale.  “Average” pain experienced during endovenous ablation was also significantly less in 
the MOCA group with both VAS - median of 10mm (3-25mm) vs 19.5mm (9-38mm), 
p=0.003 (Mann-Whitney); and Number Scale - median of 2 (0.5-4) versus 3 (2-5), p=0.004 
(Mann-Whitney).  Post hoc power analysis demonstrated 55% power at 0.05% significance 
for the VAS and 74% power at 0.05% significance for the number scale.  VAS and number 
scale showed a very strong correlation (Pearson’s r = 0.94, p<0.001). 
68% of patients described the “average” pain as lasting seconds, and there was a significant 
difference in estimated duration of “average” pain duration (76% seconds in MOCA versus 
60% seconds in RFA group, p=0.021). 
Secondary Outcomes 
Disease Specific Quality of Life - AVVQ (Figure 4) 
Overall AVVQ significantly improved from baseline to 1-month post treatment (19.3 (13.2-
28.7) to 12.8  (7.3-20.7), p<0.001) and this continued to be significant at 6 months (10.8 (4.3-
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20.5), p<0.001 (Friedman)).  Between groups, there was no significant difference at baseline, 
1-month or 6-month - 12.1 (7.3-21.2) for MOCA versus 12.9 (6.6-20.4) for RFA at 1 month 
(p=0.799); and 11.8 (7.2-20.5) for MOCA versus 9.4 (3.6-21.4) for RFA at 6 months 
(p=0.511), Figure 4. 
General Quality of Life - EQ-5D QOL and EQ-5D VAS 
Overall, EQ-5D QOL and EQ-5D VAS showed no significant change from baseline to 6 
months (Median 0.761 (0.690-0.796) at baseline, 0.761 (0.690-1.000) at 1 month and 0.761 
(0.659-1.000) at 6 months, p=0.060, Friedman).  Between groups, there was no significant 
difference in EQ-5D QOL at 1 month (MOCA - 0.761 (0.659-1.000) versus RFA - 0.761 
(0.690-1), p=0.939) or at 6 months (MOCA 0.761 (0.690-1.000) versus RFA 0.761 (0.486-
1.000), p=0.125). 
EQ-5D VAS was also not significantly different at either timepoint – at 1 month 85 (60-95) 
for MOCA versus 87 (80-90) for RFA (p=0.227) and at 6 months 85 (60-93) versus 89 (70-
95) (p=0.302). 
Clinical Severity Scoring - VCSS and VDS (Figure 5) 
Overall, VCSS significantly improved from baseline to 1 month (5 (4-7) versus 2 (1-5)) as 
did VDS (1 (1-2) versus 0 (0-1)), and both VCSS and VDS preserved this change at 6 months 
(p<0.001, Friedman).  Between groups, there was no significant difference for VCSS at either 
1 month (MOCA 2 (1-4) versus RFA 3 (1-5), p=0.096) or 6 months (MOCA 2 (1-4) versus 
RFA 2 (1-5), p=0.536) (Figure 5). 
VDS also showed no significant difference between groups at 1 month or 6 months. 
Return to Work and Return to Normal Activities 
Overall, participants returned to work at a median of 2 days (IQR 2-7) and to normal 
activities at a median of 2 days (IQR 1-6).  There was no significant difference between 
groups for either return to work (MOCA Median 3, IQR 1-7 versus RFA Median 2, IQR 2-7, 
ns) or return to normal activities (MOCA Median 2, IQR 1-4 versus RFA Median 2, IQR 1-7, 
ns). 
Technical Success of truncal ablation 
Overall complete or proximal occlusion rates were 92% at 1 month and 90% at 6 months.  
MOCA showed 93% complete or proximal occlusion at 1 month, compared to 92% in RFA.  
At 6 months the rates were 87% for MOCA versus 93% for RFA.  There was no significant 
difference in occlusion rates at 1 month or 6 months (p=0.403 and p=0.483).  Occlusion 
status had no significant effect on clinical or quality of life scores. 
Complications 
There were 3 cases of minor phlebitis along the treated vein in the MOCA group and 2 in the 
RFA group.  2 deep vein thromboses (DVTs) occurred (1.2%) - 1 in each group.  The MOCA 
DVT was a tongue of thrombus into the common femoral vein occluding <50% of the vein 
diameter (corresponding to Endovascular Treatment Induced Thrombosis stage 2 
19
), and the 
RFA DVT was a calf vein thrombus.  Neither DVT had had avulsions performed.  There 
were no patient reported cases of sensory disturbance at either clinical follow-up.  No further 
procedures were required after initial treatment at 6 months of follow-up.  No difference in 
cosmetic appearance or satisfaction was reported by patients at clinical follow-up.  There 
were no significant differences in complications between groups. 
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Discussion 
Varicose veins and chronic venous disease is a benign but progressive and pervasive disease.  
The treatment options have been transformed with endovenous ablation, allowing movement 
from the operating theatre to the outpatient suite.  Recently clinicians have begun searching 
for fine point percentage benefits in treatment 
20
. 
This study shows that tumescentless treatment using MOCA for truncal veins has a reduced 
pain profile for truncal procedure, whilst retaining similar 6 month occlusion rates, as 
compared to RFA.  Patients improved similarly in both groups with respect to disease 
specific clinical scoring and disease specific quality of life values at all time points.  The 
MOCA group did show a significantly larger improvement in AVVQ from baseline to 6-
months, despite no significant difference in baseline or 6-month follow-up group values.  
This difference of 3.3 AVVQ points falls below the clinically significant threshold of 5 points 
used for previous studies 
11,12
.    On simple group comparison, patients in the MOCA group 
also had an improved generic quality of life outcomes (EQ-5D QOL) at 6 months, despite 
similar post-operative complication rates.  However, once corrected via linear regression for 
baseline differences there was no significant difference.  No significant improvement was 
found from baseline to 6 months due to multiple testing correction (6 month data was 
significantly improved from baselin  when assessed directly) and loss to follow-up.  This 
study was not prospectively powered to assess generic or disease QOL.  It may also be 
possible that due to the severity of disease treated in this cohort, the reversibility of QOL 
detriment is limited 
21
. 
The occlusion rates at 6 months are equivalent for both modalities, however, both the RFA 
and MOCA groups had lower rates of occlusion than expected from the published literature. 
In the most recent study of long-term follow-up, a total or proximal occlusion rate of 92.7% 
at 5 years post RFA has been reported 
18
.  However, a recent study comparing open surgery 
to endovenous laser ablation found a 41% recurrence rate at 5 years 
22
.  The findings of this 
study may be secondary to detailed and independent post-operative duplex scanning or it may 
represent real world efficacy of these treatment types.  The vascular scientists performing the 
follow-up scans were experienced in the post-operative appearances of both techniques.  It is 
unlikely that these rates are due to poor technique, due to extensive experience in all 
operators prior to commencement of the study (there was no “roll-in” period).  Longer 
follow-up is needed to give detailed evidence of the robustness of the techniques.  The total 
number of patients without successful occlusion at 1 month was 11 and at 6 months was 12, 
which limits the inferences that can be drawn from such occlusion rates.   
Thus this study supports the hypothesis that MOCA is an effective treatment for truncal vein 
incompetence and subjects the patient to a less painful ablative procedure.  Additionally, this 
study provides evidence that MOCA with simultaneous phlebectomy is safe and effective in 
the short term. 
The study was powered at 90% power and 5% significance to detect a 20mm difference in 
mean pain scores on VAS, with the observed difference in medians found being 19mm.  This 
protocol power calculation required 47 patients per treatment group.  However, target 
recruitment was inflated to 170 patients to compensate for expected 50% loss to follow-up.  
121 patients (71%) attended 6-month follow-up.  The study treated 165 patients, and post hoc 
power calculations with this data show that the for pain scores, the study had 91% power at 
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0.05% significance criterion. 
The use of both a VAS and a number scale has provided evidence of their equivalence. 
The full study showed no significant reduction in pain scores from the initial report 
10
 
suggesting that there was no time dependent decrease in pain score to indicate a learning 
curve during the study. 
This study was limited by lack of treatment blinding for the patients and interventional 
clinicians.  This was due to the technical differences between devices i.e. tumescent 
injections in the RFA group and device vibration in the MOCA group.  Follow-up 
appointments and ultrasound scanning were treatment blind. 
A further limitation of this study is the lack of long term follow-up - only short term 
occlusion rates are assessed in this study, with the primary outcome obtained at the time of 
procedure.  Operating time was not recorded in this study, however all cases were performed 
in standardized theatre sessions in single slots with 1 surgeon performing all tasks, and 74% 
of patients also underwent simultaneous phlebectomy. 
A major limitation of all tumescentless techniques is how to treat varicosities left after truncal 
ablation, with level 1 evidence now supporting combined treatment with phlebectomies 
12,13
.  
This study was designed and commenced prior to the completion of latest trial, but took into 
consideration the fact that phlebectomies cause pain, and so pain scores taken after truncal 
ablation but before any phlebectomies were completed.  This therefore represents a 
significant limitation to the outcomes of this trial, as the pain scores reported above do not 
assess the complete treatment, except for those patients who did not undergo phlebectomy. 
However, similar numbers of patients underwent phlebectomies in both treatment groups.  In 
the context of tumescentless truncal ablation, the use of phlebectomies requires the use of 
additional local or tumescent anaesthesia, so further injections are not avoided.  Indeed, the 
phlebectomies may be the over-riding cause of pain.  However, tumescentless techniques still 
obviate the need for injections in the proximal thigh and groin which may be more painful 
than distal injection in the leg.  This would require further study to delineate.  Additionally, 
volume of tumescent anaesthesia used was not formally documented. 
This study did not assess pain scores after phlebectomy or after the periprocedural period. 
Treatment of the varicosities with foam sclerotherapy in combination with truncal ablation is 
an alternative technique but has yet to be assessed formally in an appropriately powered 
randomised study, however previous work has supported its use in principle 
23
.  MOCA 
presents a dilemma due to sclerosant dose limitations, with European consensus guidelines 
advocating a maximum dose of 10ml of <3% concentration liquid sodium tetradecyl sulphate 
sclerosant or 2mg/kg polidocanol sclerosant and 10ml of foam sclerosant 
24
.  Additionally the 
treatment techniques leads to a variable dosage of scleroant per cm treated, dependent on vein 
diameter, and governed by the Vascular Insights MOCA sclerosant guidance and instructions 
for use.  Alternative tumescentless devices do not have such dose limitations, but published 
data is lacking.  Studies examining volume limits would be beneficial to help guide both 
MOCA and pure sclerotherapy techniques. 
Further studies examining pain experienced during combined phlebectomy and truncal 
ablation procedures would be of great benefit to ascertain the difference treatment devices 
make in simultaneous therapy – for assessment of the whole treatment. 
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Conclusion 
Mechanochemical truncal ablation offers patients reduced intra-procedural pain with 
equivalent technical success compared to radiofrequency truncal ablation at 6 months.  
Patients have equivalent disease specific quality of life and clinical outcomes, and returned to 
work and normal activities at similar times. 
Further work with larger studies and extended follow-up are needed to assess long term 
outcomes and recurrence rates. 
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Figure Legends 
Figure 1: 
VVCVV Consort Diagram 
 
Figure 2: 
Maximum Pain Score during procedure for Mechanochemical Ablation group (MOCA) and 
Radiofrequency Ablation (RFA) (a) – Visual Analogue Scale, (b) – Number Scale. 
 
Figure 3: 
Average Pain Score during procedure for Mechanochemical Ablation group (MOCA) and 
Radiofrequency Ablation (RFA) (a) – Visual Analogue Scale, (b) – Number Scale. 
 
Figure 4: 
Aberdeen Varicose Vein Questionnaire scores at baseline, 1 month and 6 months follow-up -  
by treatment group - Mechanochemical Ablation group (MOCA) and Radiofrequency 
Ablation (RFA). 
 
Figure 5: 
Venous Clinical Severity Score (VCSS) scores at baseline, 1 month and 6 months follow-up - 
by treatment group - Mechanochemical Ablation group (MOCA) and Radiofrequency 
Ablation (RFA). 
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Table Legends 
Table 1: 
Patient Demographics - Mechanochemical Ablation group (MOCA) and Radiofrequency 
Ablation (RFA). 
 
Table 2: 
Treatment Characteristics -  Mechanochemical Ablation group (MOCA) and Radiofrequency 
Ablation (RFA). 
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 Total MOCA RFA Difference? 
n 170 87 83 ns 
Male 70 (41.2%) 37 (42.5%) 33 (39.8) ns (0.714) 
AgeMedian 50 54.5 48 ns (0.099) 
GSV 147 (86.5%) 77 (88.5%) 70 (84.3%) ns (0.427) 
BMI >30 20 (13.4%) 13 (16.7%) 7 (9.9%) ns (0.223) 
CEAPMedian 4 4 4 ns (0.627) 
VCSSMedian 5 6 5 ns (0.112) 
VDSMedian 1 1 1 ns (0.135) 
AVVQ 19.303 19.546 18.888 ns (0.592) 
EQ5D QOLMedian 0.761 0.761 0.730 ns (0.989) 
EQ5D VASMedian 81.0 84.5 80.0 ns (0.050) 
Table 1 Patient Demographics 
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 Total MOCA RFA Difference? 
n 165 83 82 ns 
Length of vein 
treated (GSV) 
mm 
364 359 373 ns 
Length of vein 
treated (SSV) 
mm 
205 227 166 ns 
Concomitant 
Avulsions 
74% 68% 76% ns 
Median Number 
of Avulsions 
4 4 4 ns 
Median Vein 
Diameter mm 
7 7 7 ns 
Table 2 Treatment Characteristics 
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Screening
n=240
Randomisation
n=170
Allocated to 
MOCA
n=87
Received MOCA
n=83 (95%)
Attended 1 month 
Follow-Up
n=69 (79%)
Attended 6 month 
Follow-Up
n=62 (71%)
Allocated to RFA
n=83
Received RFA
n=82 (99%)
Attended 1 month 
Follow-Up
n=60 (72%)
Attended 6 month 
Follow-Up
n=59 (71%)
Recruitment
n=170
Did Not 
Receive 
MOCA
n=4 (5%)
Did Not 
Receive 
n=1 (1%)
Excluded
n=170
Refused participation n = 20
Did not meet inclusion criteria n = 50
Page 18 of 31Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
0
20
40
60
80
10
0
VA
S 
M
ax
im
um
 P
ai
n 
(m
m)
MOCA RFA
Page 19 of 31 Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
0
2
4
6
8
10
N
um
be
r S
ca
le
 M
ax
im
um
 P
ai
n
MOCA RFA
Page 20 of 31Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
0
20
40
60
80
VA
S 
Av
er
ag
e 
Pa
in
 (m
m)
MOCA RFA
Page 21 of 31 Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
0
2
4
6
8
10
N
um
be
r S
ca
le
 A
ve
ra
ge
 P
ai
n
MOCA RFA
Page 22 of 31Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
0
20
40
60
80
MOCA RFA
AVVQ − Baseline AVVQ − 30 Day
AVVQ − 6 Month
Page 23 of 31 Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
0
5
10
15
20
25
MOCA RFA
VCSS − Baseline VCSS − 30Day
VCSS − 6Months
Page 24 of 31Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
Figure Legends 
Figure 1: 
VVCVV Consort Diagram 
 
Figure 2: 
Maximum Pain Score during procedure for Mechanochemical Ablation group (MOCA) and 
Radiofrequency Ablation (RFA) (a) – Visual Analogue Scale, (b) – Number Scale. 
 
Figure 3: 
Average Pain Score during procedure for Mechanochemical Ablation group (MOCA) and 
Radiofrequency Ablation (RFA) (a) – Visual Analogue Scale, (b) – Number Scale. 
 
Figure 4: 
Aberdeen Varicose Vein Questionnaire scores at baseline, 1 month and 6 months follow-up - 
by treatment group - Mechanochemical Ablation group (MOCA) and Radiofrequency 
Ablation (RFA). 
 
Figure 5: 
Venous Clinical Severity Score (VCSS) scores at baseline, 1 month and 6 months follow-up - 
by treatment group - Mechanochemical Ablation group (MOCA) and Radiofrequency 
Ablation (RFA). 
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Table 1: 
Patient Demographics - Mechanochemical Ablation group (MOCA) and 
Radiofrequency Ablation (RFA). 
 
Table 2: 
Treatment Characteristics -  Mechanochemical Ablation group (MOCA) and 
Radiofrequency Ablation (RFA). 
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all necessary permissions for the reproduction of any copyright works not owned by me (including 
artistic works, e.g. illustrations, photographs, charts, maps, other visual material, etc.) contained in the 
Contribution and any Supplemental Material I provide and that I have acknowledged the source(s), that 
the Contribution and any Supplemental Material I provide contain no violation of any existing copyright, 
other third party rights or any libellous or untrue statements and do not infringe any rights of others, and 
I agree to indemnify, defend and hold harmless SAGE against any claims in respect of the above 
warranties. I further agree to be bound by the Conditions of Publication provided herein as part of this 
Agreement which outline the circumstances under which work may be reused. 
 
Declaration of Conflicting Interests 
 
I certify that: 
1. All forms of financial support, including pharmaceutical company support, are acknowledged in 
the Contribution 
2. Any commercial or financial involvements that might present an appearance of a conflict of 
interest related to the Contribution are disclosed in the covering letter accompanying the 
Contribution and all such potential conflicts of interest will be discussed with the Editor as to 
whether disclosure of this information with the published Contribution is to be made in the 
Journal. 
3. I have not signed an agreement with any sponsor of the research reported in the Contribution 
that prevents me from publishing both positive and negative results or that forbids me from 
publishing this research without the prior approval of the sponsor. 
4. I have checked in the manuscript submission guidelines whether this Journal requires a 
Declaration of Conflicting Interests and complied with the requirements specified where such a 
policy exists. 
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It is not expected that the details of financial arrangements should be disclosed. If the Journal does 
require a Declaration of Conflicting Interests and no conflicts of interest are declared, the following will 
be printed with your article: ‘None Declared’. 
 
Supplemental Material 
 
Supplemental Material includes all material related to the Contribution, but not considered part of the 
Contribution, provided to SAGE by you as the Contributor.  Supplemental Material may include but is not 
limited to datasets, audio-visual interviews including podcasts (audio only) and vodcasts (audio and 
visual), appendices, and additional text, charts, figures, illustrations, photographs, computer graphics, 
and film footage.  Your grant of a non-exclusive right and license for these materials to SAGE in no way 
restricts re-publication of Supplemental Material by you or anyone authorized by you. 
 
Termination 
 
SAGE, in its sole, absolute discretion, may determine that the Contribution should not be published in 
the Journal.  If in the rare circumstance the decision is made not to publish the Contribution after 
accepting it for publication, then all rights in the Contribution granted to SAGE shall revert to you and 
this Agreement shall be of no further force and effect, and neither you nor SAGE will have any obligation 
to the other with respect to the Contribution. 
 
Counterparts; Facsimile 
 
This Agreement may be executed in counterparts each of which shall be deemed the original, all of 
which together shall constitute one and the same Agreement.  A faxed copy or other electronic copy 
shall be deemed as an original. 
 
Electronic Signature Authorization 
 
This transaction may be conducted by electronic means and the parties authorize that their electronic 
signatures act as their legal signatures of this Agreem nt. This Agreement will be considered signed by 
a party when his/her/its electronic signature is transmitted. Such signature shall be treated in all respects 
as having the same effect as an original handwritten signature. (You are not required to conduct this 
transaction by electronic means or use an electronic signature, but if you do so, then you hereby give 
your authorization pursuant to this paragraph.) 
 
Modification; Entire Agreement; Severability 
 
No amendment or modification of any provision of this Agreement shall be valid or binding unless made 
in writing and signed by all parties. This Agreement constitutes the entire agreement between the parties 
with respect to its subject matter, and supersedes all prior and contemporaneous agreements, 
understandings and representations.  The invalidity or unenforceability of any particular provision of this 
Agreement shall not affect the other provisions, and this Agreement shall be construed in all respects as 
if any invalid or unenforceable provision were omitted. 
 
Governing Law; Arbitration 
 
This Agreement shall be deemed to be a contract made in England and shall be construed and applied 
in all respects in accordance with English law and the parties submit and agree to the jurisdiction of the 
English courts. 
 
If any difference shall arise between you and SAGE touching the meaning of this Agreement or the 
rights and liabilities of the parties thereto, the same shall be referred to the arbitration of two persons 
(one to be named by each party) or their mutually agreed umpire, in accordance with the provision of the 
England Arbitration Act 1996 or any amending or substituted statute for the time being in force. 
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Your rights as author 
 
• You retain copyright in your work. 
• You may do whatever you wish with the version of the article you submitted to the journal – 
version 1. 
• Once the article has been accepted for publication, you may post the accepted version (version 
2) of the article on your own personal website, your department’s website or the repository of 
your institution without any restrictions. 
• You may not post the accepted version (version 2) of the article in any repository other than 
those listed above (i.e. you may not deposit in the repository of another institution or a subject 
repository) until 12 months after first publication of the article in the journal. 
• You may use the published article (version 3) for your own teaching needs or to supply on an 
individual basis to research colleagues, provided that such supply is not for commercial 
purposes. 
• You may use the article (version 3) in a book you write or edit any time after publication in the 
journal. 
• You may not post the published article (version 3) on any website or in any repository without 
permission from SAGE. 
• When posting or re-using the article please provide a link to the appropriate DOI for the 
published version of the article on SAGE Journals (http://online.sagepub.com). 
 
All commercial or any other re-use of the published article should be referred to SAGE. More 
information can be found at: http://www.sagepub.co.uk/journalsPermissions.nav 
 
When posting or re-using the article, you should provide a link/URL from the article posted to the SAGE 
Journals Online site where the article is published:  http://online.sagepub.com and please make the 
following acknowledgment: ‘The final, definitive version of this paper has been published in 
<journal>, Vol/Issue, Month/Year by SAGE Publications Ltd, All rights reserved. © [The Author(s)] 
 
SAGE’s use of the work 
 
Although you have retained the copyright in your article, you have granted SAGE an exclusive license to 
use it. This helps us to ensure adequate protection against infringement of copyright protected material 
through breach of copyright or piracy anywhere in the world. It also ensures that requests by third 
parties to reprint or reproduce a contribution, or part of it in any format, are handled efficiently in 
accordance with our general policy which encourages dissemination of knowledge inside the framework 
of copyright. 
Where practicable, we advise third parties inform you of their requests to re-use your material.  This 
does not apply to blanket arrangements covering the Journal as a whole. Please keep our mailing list up 
to date with your institutional or business address changes to help us to do this.  Inadvertent failure to 
inform you will not constitute a material breach of this Agreement. 
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Your responsibilities as author: inclusion of other copyright material 
 
SAGE is sympathetic to the needs of scholars to include other copyright material, and is happy to 
provide guidance on this.  Responsibility for obtaining permission to use any other copyright material 
rests with you as the author of the Contribution. 
 
If your Contribution includes material which is not your copyright, you are responsible for submitting with 
your manuscript the written permission from those who control copyright in that material to include it and 
reproduce it within your Contribution. In most cases this will be the publisher of the work.  As the Journal 
is available in both print and electronic media and may be translated or archived, this permission needs 
to be for all media in all languages in perpetuity. You are responsible for the payment of any permission 
fees. 
 
Fair Dealing information for your reference: 
 
Fair Dealing provisions under UK  copyright law and/or the Fair Use provisions under US law for use of 
material in review, and/or other International Copyright Laws allow for the limited use of third party 
copyright materials in particular circumstances, without the requirement to obtain permission as above. 
 
The term ‘fair dealing’ is not defined in UK legislation itself but should be viewed from a qualitative as 
well as a quantitative perspective. There are no set rules which cover what is or is not fair dealing. For 
guidance: 
 
 
• Fair dealing can only apply to material used for specific purposes including those of criticism 
and review and news reporting and incidental use. 
 
• Permission should always be sought where reproduction could reasonably be construed as 
competing with the sale of the original source and/or where the amount of copying is 
substantial. 
 
• Whether you are including material with permission, or on the basis that it falls under ‘fair 
dealing’ or ‘fair use’, you must include acknowledgement of the copyright holder and original 
publication of the material. 
 
If you are in doubt, please ask for advice from SAGE or the journal editor. 
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